仁和药业：股票交易异常波动公告

Core Viewpoint - Renhe Pharmaceutical announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 20.42% over two consecutive trading days on August 20 and 21, 2025 [1] Group 1: Company Operations - The company confirmed that its recent operational conditions are normal and that there have been no significant changes in the internal and external operating environment [1] - There are no undisclosed significant matters involving the company, its controlling shareholders, or actual controllers [1] Group 2: Product Development - The company's subsidiary has developed a brain-machine interaction smart glasses product named ULook, which currently only has sample production and has not yet generated sales revenue [1] - The ULook product's current status does not have a significant impact on the company's overall performance [1]